Product overview: the scale is 8.5 billion, and it was established 14. 1 year, with an annualized income of 20. 14%.

Highlight: Since the development of Public Offering of Fund in China for 2 1 year, a total of 15 cattle foundations have been produced, and the total income has exceeded 10 times. Including: Huaxia Market, Harvest Growth, Xingquan Trend Investment, Bosera Theme Industry, Guo Fu Tianhui, etc.

What the fund manager hasn't changed since the first day is Guo Fu Tianhui. During 14 years, A-shares have experienced ups and downs, and fund manager Zhu Shaoxing has been sticking to the front line to serve investors, which is really a model of the industry.

2. China-Europe Shanghai-Hong Kong-Shenzhen A(002685)?

Product Description: The scale is 500 million, it was established 3. 1 year, and the annualized income is 12.59%.

Highlight: Cao Mingchang, a CEIBS fund, currently manages 7 funds, and his management of CEIBS value discovery is quite famous. There are two main reasons for the old drivers to choose the central European flood peak Shanghai-Hong Kong-Shenzhen A:

First, the fund is a Shanghai-Hong Kong-Shenzhen fund and can invest in Hong Kong stocks. At present, the Hong Kong stock market has great investment value, and 202 1 is worth looking forward to.

Second, this fund has been managed by Cao Mingchang since its establishment in June, 20 1 16, and it is also the product with the highest annual income of all the seven funds he manages at present.

The fund's third quarterly report of 20 19 shows that its top ten positions are not only equipped with A-share bull stocks such as Gree Electric and Luxshare, but also equipped with a number of high-quality companies in Hong Kong, including Tencent Holdings, Yu Shun Optical Technology, Haidilao and China Biopharmaceutical. The fund's yield in 20 19 was 42.85%, and it outperformed the Shanghai and Shenzhen 300 Index for three consecutive years from 20 17 to 20 19. ?

3. China-Europe Medical Innovation A(006228)?

Product overview: The scale is 65.438+0.5 billion yuan, it was established 0.8 years ago, and the total income is 24.25%. Reasons for concern: Gulen is the only doctor of medicine who manages pharmaceutical funds in China. He was once a member of the "New Wealth First" team and has more than 8 years of investment and research experience in the pharmaceutical industry. At present, she manages three funds: China-Europe Medical Health, China-Europe Mingrui New Starting Point and China-Europe Medical Innovation, among which China-Europe Medical Health is the most famous.

There are two reasons for recommendation:

First, the scale of the fund is too small, and it is easier to obtain excess returns.

Second, the fund mainly invests in the field of medical innovation. Under the background of centralized procurement, the investment opportunities for innovative drugs in the future are more certain.

In addition, no more than 50% of the fund's positions can be invested in Hong Kong stocks, which can capture investment opportunities of high-quality companies in a wider scope and cover more leading pharmaceutical and biological enterprises.

Matters needing attention in fund purchase:

Even if it is a good fund, you should buy it when the price is right or low, in order to make more money. Many people lose money in investment funds for many reasons, even if they invest in the target, they may not be able to make money.

To put it bluntly, investment is the realization of cognition. If you only know one code, you are likely to invest in the same fund. Others make money by investing, but they lose money by investing themselves.

Therefore, before investing in 202 1, we must thoroughly study and understand before reinvesting. Because no one can rely on luck and others to recommend investment for decades and succeed.